Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ESLA Stock Forecast 2026-2027
$1.26
Current Price
$52.96M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to ESLA Price Targets
+534.9%
To High Target of $8.00
+534.9%
To Median Target of $8.00
+534.9%
To Low Target of $8.00
ESLA Price Momentum
+17.8%
1 Week Change
0.0%
1 Month Change
+37.0%
1 Year Change
-19.2%
Year-to-Date Change
-60.0%
From 52W High of $3.15
+72.6%
From 52W Low of $0.73
📊 TOP ANALYST CALLS
Did ESLA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Estrella Immunopharma is one of their latest high-conviction picks.
Latest ESLA Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, ESLA has a bullish consensus with a median price target of $8.00 (ranging from $8.00 to $8.00). The overall analyst rating is N/A (N/A/10). Currently trading at $1.26, the median forecast implies a 534.9% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Jason Kolbert at D. Boral Capital, projecting a 534.9% upside. Conversely, the most conservative target is provided by Jason Kolbert at D. Boral Capital, suggesting a 534.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ESLA Analyst Ratings
1
Buy
0
Hold
0
Sell
ESLA Price Target Range
Low
$8.00
Average
$8.00
High
$8.00
Current: $1.26
Latest ESLA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ESLA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 9, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $8.00 |
| Jan 28, 2026 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $8.00 |
| Nov 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| Aug 12, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| Jun 3, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| May 29, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| Feb 21, 2025 | D. Boral Capital | Jason Kolbert | Buy | Maintains | $16.00 |
| Feb 18, 2025 | D. Boral Capital | Jason Kolbert | Buy | Initiates | $16.00 |
Estrella Immunopharma Inc. (ESLA) Competitors
The following stocks are similar to Estrella Immunopharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
ESLA
Estrella Immunopharma
mkt cap
52.96M
Estrella Immunopharma Inc. (ESLA) Financial Data
Estrella Immunopharma Inc. has a market capitalization of $52.96M with a P/E ratio of -4.7x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -171.1%.
Valuation Metrics
Market Cap
$52.96M
Enterprise Value
$45.96M
P/E Ratio
-4.7x
PEG Ratio
N/A
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+3.4%
Current Ratio
0.2x
Debt/Equity
0.0x
ROE
-171.1%
ROA
-164.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Estrella Immunopharma Inc. (ESLA) Business Model
About Estrella Immunopharma Inc.
What They Do
Develops innovative therapies for cancer and serious diseases.
Business Model
The company focuses on researching and developing advanced treatment options, particularly in the biopharmaceutical sector. It generates revenue by advancing novel drug candidates through clinical trials and eventually bringing them to market as effective therapies for unmet medical needs.
Additional Information
Estrella Immunopharma is committed to scientific excellence and personalized medicine, addressing the increasing demand for targeted therapies. Its innovations aim to significantly impact healthcare treatments and improve patient outcomes.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
0
CEO
Dr. Cheng Liu Ph.D.
Country
United States
IPO Year
2021
Website
www.estrellabio.comEstrella Immunopharma Inc. (ESLA) Latest News & Analysis
Latest News
Quick Summary
Estrella Immunopharma (Nasdaq: ESLA) reported positive Phase I results for its ARTEMIS® T-cell therapies at the 2026 Tandem Meetings, focusing on cancer and autoimmune diseases.
Why It Matters
Positive Phase I results from Estrella's ARTEMIS® therapies could signal potential advancements in cancer and autoimmune treatments, impacting stock valuation and investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Estrella Immunopharma (Nasdaq: ESLA) will present results from its STARLIGHT-1 phase I trial on CD19 and CD22-targeted ARTEMIS® therapies at the 2026 ASTCT & CIBMTR Tandem Meetings.
Why It Matters
The presentation of positive phase I results for Estrella's ARTEMIS® therapies could signal advancements in cancer treatment, potentially boosting the company's stock and attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Estrella Immunopharma, Inc. has signed agreements with a healthcare-focused institutional investor to sell common stock and pre-funded warrants, supporting its development of targeted T-cell therapies.
Why It Matters
Estrella Immunopharma's agreement with a healthcare investor indicates confidence in its T-cell therapies, potentially driving stock value and attracting further investment interest in the biotech sector.
Source: Business Wire
Market Sentiment:
Neutral
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
2 months ago
Quick Summary
Estrella Immunopharma, Inc. closed a registered direct offering, selling 4,063,290 shares of common stock and 1,000,000 pre-funded warrants to a healthcare-focused institutional investor.
Why It Matters
Estrella Immunopharma's direct offering raises capital, potentially funding further development of its therapies. This could impact share value and investor confidence in its growth prospects.
Source: Business Wire
Market Sentiment:
Neutral
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
3 months ago
Quick Summary
Estrella Immunopharma's STARLIGHT-1 trial received a favorable safety review from an independent DSMB, supporting its CD19 and CD22-targeted ARTEMIS® T-cell therapies for cancer and autoimmune diseases.
Why It Matters
The favorable safety review of Estrella's ARTEMIS® therapies may boost investor confidence, potentially leading to increased stock demand and a positive outlook for future clinical trials.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Estrella Immunopharma (NASDAQ: ESLA) completed the second dose cohort of its Phase I trial for EB103, a CD19-targeted therapy for Advanced B-Cell Non-Hodgkin's Lymphoma.
Why It Matters
The completion of the second dose cohort in a Phase I clinical trial suggests progress in drug development, potentially increasing Estrella's market value and attracting investor interest.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About ESLA Stock
What is Estrella Immunopharma Inc.'s (ESLA) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Estrella Immunopharma Inc. (ESLA) has a median price target of $8.00. The highest price target is $8.00 and the lowest is $8.00.
Is ESLA stock a good investment in 2026?
According to current analyst ratings, ESLA has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.26. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ESLA stock?
Wall Street analysts predict ESLA stock could reach $8.00 in the next 12 months. This represents a 534.9% increase from the current price of $1.26. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Estrella Immunopharma Inc.'s business model?
The company focuses on researching and developing advanced treatment options, particularly in the biopharmaceutical sector. It generates revenue by advancing novel drug candidates through clinical trials and eventually bringing them to market as effective therapies for unmet medical needs.
What is the highest forecasted price for ESLA Estrella Immunopharma Inc.?
The highest price target for ESLA is $8.00 from Jason Kolbert at D. Boral Capital, which represents a 534.9% increase from the current price of $1.26.
What is the lowest forecasted price for ESLA Estrella Immunopharma Inc.?
The lowest price target for ESLA is $8.00 from Jason Kolbert at D. Boral Capital, which represents a 534.9% increase from the current price of $1.26.
What is the overall ESLA consensus from analysts for Estrella Immunopharma Inc.?
The overall analyst consensus for ESLA is bullish. Out of 1 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $8.00.
How accurate are ESLA stock price projections?
Stock price projections, including those for Estrella Immunopharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 12:14 PM UTC